Latest Regulatory News

The Star Entertainment Group reported steady Q4 FY25 revenue of $270 million but widened its EBITDA loss to $27 million, reflecting ongoing regulatory pressures and operational challenges. The company secured $233 million from strategic investors Bally’s Corporation and Investment Holdings, while negotiations continue over its Brisbane joint venture exit.

Forrestania Resources has voluntarily suspended trading on the ASX as it prepares to announce a significant acquisition, signaling a potentially transformative move for the mining company.

Vital Metals Limited has released a comprehensive Scoping Study for its Tardiff Rare Earths deposit in Canada, revealing strong economic potential with an 11-year mine life and significant neodymium-praseodymium resources.

Syrah Resources has resumed production at its Balama graphite mine after a year-long halt and is advancing sales at its US Vidalia anode material facility, supported by new US tariffs on Chinese imports and a $70 million equity raise.

Nickel Industries reported record ore sales and EBITDA at its Hengjaya Mine for the June 2025 quarter, alongside significant progress on key projects and sustainability initiatives.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Sequoia Financial Group has responded to an ASX price query, denying any undisclosed material information behind recent trading fluctuations and reaffirming compliance with listing rules amid ongoing ASIC investigations.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Bowen Coking Coal has appointed voluntary administrators after failing to secure fresh capital or negotiate with key creditors, reflecting mounting challenges in Queensland's coal sector. The administration aims to enable a sale or recapitalisation while maintaining operations at its Burton Mine Complex.